Optimizerx Corporation (OPRX)
NASDAQ:OPRX
Want to see OPRX full AI Analyst Report?
Top Page
OptimizeRx
(NASDAQ:OPRX)
Select Model
Select Model
Rating:66Neutral
Price Target:
$7.50
▲(4.60% Upside)
Action:ReiteratedDate:04/10/26
The score is driven primarily by stronger financial health and cash generation alongside improved profitability and low leverage. These positives are tempered by weak technical trends and a high P/E, plus conservative 2026 revenue outlook and near-term demand/contracting headwinds discussed on the earnings call.
Positive Factors
Cash Generation
Material free cash flow in 2025 ($18.7M) strengthens the company’s ability to fund product development, pay down debt, and pursue buybacks without external financing. Sustained cash generation improves resilience across cycles and supports reinvestment into recurring-revenue initiatives.
Negative Factors
Contracted Revenue Softness
A structural pullback in contracted spend tied to a market shift away from managed services and client conservatism reduces near-term top-line visibility. If durable, this forces a longer transition to product-led revenue and could pressure multi-quarter growth until conversions scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash Generation
Material free cash flow in 2025 ($18.7M) strengthens the company’s ability to fund product development, pay down debt, and pursue buybacks without external financing. Sustained cash generation improves resilience across cycles and supports reinvestment into recurring-revenue initiatives.
Read all positive factors
OptimizeRx (OPRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$115.20M
Dividend YieldN/A
Average Volume (3M)488.11K
Price to Earnings (P/E)44.3
Beta (1Y)1.95
Revenue Growth18.78%
EPS GrowthN/A
CountryUS
Employees128
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding18,762,203
10 Day Avg. Volume462,507
30 Day Avg. Volume488,107
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)1.77
Price to Sales (P/S)2.08
P/FCF Ratio12.19
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue1.08
Enterprise Value/Gross Profit1.70
Enterprise Value/Ebitda7.20
Forecast
1Y Price Target
$15.20Price Target Upside111.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.97
Revenue Forecast (FY)$121.63M
OptimizeRx Business Overview & Revenue Model
Company Description
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient supp...
How the Company Makes Money
OptimizeRx primarily makes money by providing commercial engagement and support services to pharmaceutical and life sciences customers, generally monetized through contracts tied to campaigns, programs, or subscriptions that place brand and patien...
OptimizeRx Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call presented a largely positive operational and financial performance for 2025: strong cash generation, improved profitability, high net revenue retention (116%), productivity gains, meaningful DAAP momentum and a $10M share repurchase authorization. However, management flagged near-term top-line risks driven by a market shift away from managed services, conservative client behavior tied to MFN negotiations, shorter contract durations, and a Q4 gross margin mix that is unlikely to repeat. Guidance for 2026 is conservative on revenue (flat to modestly higher) while maintaining healthy adjusted EBITDA expectations, reflecting a focus on profitability and cash usage for debt reduction and opportunistic buybacks. Overall, the positives around profitability, cash flow, recurring-revenue progress and customer traction outweigh the near-term revenue headwinds.Positive Updates
Quarterly and Full-Year Revenue & Profitability
Q4 revenue of $32.2M and full-year 2025 revenue of $109.4M. Q4 adjusted EBITDA of $12.0M and full-year adjusted EBITDA of $24.3M, delivering adjusted EBITDA margins above 20% for the year and achieving Rule of 40 performance.
Negative Updates
Near-Term Contracted Revenue Softness
Year-to-date contracted revenue is softer vs. last year, largely due to a market shift away from managed services and more conservative client contracting behavior related to most favored nation (MFN) negotiations. Management estimates contracted revenue running roughly 15%-20% behind where it normally would be after removing managed services.
Read all updates
Q4-2025 Updates
Positive
Negative
Quarterly and Full-Year Revenue & Profitability
Q4 revenue of $32.2M and full-year 2025 revenue of $109.4M. Q4 adjusted EBITDA of $12.0M and full-year adjusted EBITDA of $24.3M, delivering adjusted EBITDA margins above 20% for the year and achieving Rule of 40 performance.
Read all positive updates
Company Guidance
Management updated 2026 guidance to revenue of $109–$114 million and adjusted EBITDA of $21–$25 million, taking a more conservative top‑line view despite fiscal 2025 strength (FY2025 revenue $109.4M, adjusted EBITDA $24.3M; Q4 revenue $32.2M, Q4 adjusted EBITDA $12M), having achieved Rule of 40 and adjusted EBITDA margins above 20%, generated nearly $19M free cash flow (operating cash flow $18.7M), ended the year with $23.4M in cash and short‑term investments against $26.3M of debt, saw Q4 gross margin of 74.8% but expects mid‑60% gross margin in 2026, noted managed‑services drove roughly $9M of 1H25 revenue and will be minimal in 2026, contracted revenue is running ~15–20% below prior year ex‑managed services, net revenue retention is 116%, average revenue per top‑20 pharma $2.8M (down from $3.0M), revenue per FTE $839K (up from $701K), and the Board authorized a $10M share repurchase program while prioritizing debt paydown and profitable growth.OptimizeRx Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
83
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 109.43M | 92.13M | 71.52M | 62.45M | 61.29M |
| Gross Profit | 69.27M | 59.38M | 42.90M | 38.97M | 35.64M |
| EBITDA | 16.39M | -8.90M | -21.31M | -9.42M | 2.33M |
| Net Income | 5.13M | -20.11M | -17.57M | -11.44M | 378.08K |
Balance Sheet | |||||
| Total Assets | 176.92M | 171.17M | 183.37M | 134.65M | 140.99M |
| Cash, Cash Equivalents and Short-Term Investments | 23.36M | 13.38M | 13.85M | 74.14M | 84.68M |
| Total Debt | 26.10M | 33.19M | 36.82M | 234.43K | 327.71K |
| Total Liabilities | 48.62M | 54.17M | 56.82M | 8.54M | 9.61M |
| Stockholders Equity | 128.29M | 117.00M | 126.55M | 126.11M | 131.38M |
Cash Flow | |||||
| Free Cash Flow | 18.66M | 4.78M | -8.11M | 10.41M | 240.04K |
| Operating Cash Flow | 18.71M | 4.89M | -7.24M | 10.65M | 726.04K |
| Investing Cash Flow | 68.00K | -450.00K | -25.34M | -58.18M | -486.00K |
| Financing Cash Flow | -8.80M | -4.91M | 28.22M | -18.95M | 73.92M |
OptimizeRx Technical Analysis
Neutral
7.17
Price Trends
7.30
Negative
10.15
Negative
13.46
Negative
Market Momentum
-0.22
Negative
55.90
Neutral
65.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPRX, the sentiment is Neutral. The current price of 7.17 is above the 20-day moving average (MA) of 6.51, below the 50-day MA of 7.30, and below the 200-day MA of 13.46, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 55.90 is Neutral, neither overbought nor oversold. The STOCH value of 65.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OPRX.
OptimizeRx Risk Analysis
OptimizeRx disclosed 33 risk factors in its most recent earnings report. OptimizeRx reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
OptimizeRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $229.07M | 17.11 | 8.64% | 9.67% | 1.49% | 4.54% | |
69 Neutral | $621.86M | 37.76 | 5.18% | 0.52% | 4.26% | -7.27% | |
66 Neutral | $115.20M | 44.33 | 4.22% | ― | 18.78% | ― | |
66 Neutral | $385.93M | -18.65 | 2.49% | ― | 2.26% | ― | |
66 Neutral | $1.96B | 33.30 | 1.64% | ― | 7.86% | -2.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $378.41M | -3.99 | -116.98% | ― | 18.56% | -23.69% |
* Healthcare Sector Average
OPRX
OptimizeRx
6.23
-3.41
-35.37%
TBRG
TruBridge
25.70
-0.38
-1.46%
HSTM
HealthStream
20.76
-12.45
-37.49%
OMCL
Omnicell
41.42
10.04
31.99%
SPOK
Spok Holdings
10.69
-4.18
-28.12%
SOPH
SOPHiA GENETICS
5.22
2.20
72.85%
OptimizeRx Corporate Events
Business Operations and StrategyExecutive/Board Changes
OptimizeRx Adds Microsoft Health Leader to Board
Positive
Apr 9, 2026
On April 8, 2026, OptimizeRx announced the appointment of Mary Varghese Presti, Corporate Vice President and Chief Operating Officer of Microsoft’s Health Life Sciences division, to its board as an independent director. Her addition is part...
Business Operations and StrategyStock BuybackFinancial DisclosuresPrivate Placements and Financing
OptimizeRx Authorizes $10 Million Share Repurchase Program
Positive
Mar 5, 2026
On March 2, 2026, OptimizeRx amended its financing agreement to extend the maturity date by two years to October 11, 2029, lengthen the period during which a 1% premium applies, and secure flexibility to repurchase up to $10 million of stock by Ma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.